Home>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>K22

K22

Catalog No.GC47521

An antiviral agent

Products are for research use only. Not for human use. We do not sell to patients.

K22 Chemical Structure

Cas No.: 2141978-86-9

Size Price Stock Qty
1 mg
$94.00
In stock
5 mg
$425.00
In stock
10 mg
$754.00
In stock
25 mg
$1,295.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

K22 is an antiviral agent.1 It inhibits the replication of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus 229E (HCoV-229E), feline coronavirus (FCoV), and mouse hepatitis virus (MHV) in Vero cells when used at a concentration of 40 µM. K22 inhibits the formation of double membrane vesicles, a hallmark of coronavirus replication, and inhibits viral RNA synthesis in HCoV-229E-infected MRC-5 cells. It also reduces viral titers in cells infected with various Arteriviridae or Torovirinae viruses.2

1.Lundin, A., Dijkman, R., BergstrÖm, T., et al.Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virusPLoS Pathog.10(5)e1004166(2014) 2.Rappe, J.C.F., de Wilde, A., Di, H., et al.Antiviral activity of K22 against members of the order NidoviralesVirus Res.24628-34(2018)

Reviews

Review for K22

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for K22

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.